• Users Online:2086
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2013  |  Volume : 7  |  Issue : 2  |  Page : 47-61

Hydroquinone: Homoeopathic Pathogenetic Trial

Director, Life Force Homoeopathy, Chembur, Mumbai- 400 089, Maharashtra, India

Correspondence Address:
Rajesh Shah
Life Force, 411 Krushal Commercial Complex, GM Road, Chembur, Mumbai- 400 089, Maharashtra
Login to access the Email id

Source of Support: None, Conflict of Interest: Homoeopathy India Pvt. Ltd. sponsored the HPT. The sponsor has played no role in data collection, analysis, or data interpretation. An independent team did the investigations and assessment of the symptoms; and independent, accredited laboratories carried out all the safety assessments

DOI: 10.4103/0974-7168.116621

Rights and Permissions

Background: A double-blind, randomized, placebo-controlled Homoeopathic Pathogenetic Trial (HPT/Drug Proving) of Hydroquinone was conducted, using the accepted guidelines, ethical approval and scientific documentation The potentization method was standardized. Toward enhancing the quality of HPT, the investigator proposed and evaluated the data using the Quantitative Pathogenetic Index and Qualitative Pathogenetic Index. Usable symptoms were derived from the study. The medicine was suggested for the treatment of vitiligo, based on its known toxicological effects. HPT of a new medicinal substance, using the established parameters, to evaluate symptoms in healthy volunteers was carried out using a controlled experiment. Aims: The aim of the study was to conduct a HPT using the accepted and scientific guidelines to derive clinically usable symptoms. Material and Methods: A double-blind, randomized, placebo-controlled homoeopathic pathogenetic trial was conducted in 22 volunteers (provers), out of whom 15 received Hydroquinone in 30C potency, thrice daily, for four weeks, while seven received the placebo. The volunteer's symptoms during the initial seven days of the run-in period were carefully noted, and these were used as a filter, by elimination of the same symptoms in that volunteer during the verum phase. Thorough documentation such as Informed Consent Form, approval by the Ethics Committee, laboratory investigations, and safety and ethical measures, were taken care of. The volunteers were trained to write data in the prescribed diaries which was analyzed at the end. The investigator introduced Quantitative and Qualitative Pathogenetic Indices as parameters in the evaluation of the data derived from the HPT. Results: The HPT of Hydroquinone exhibited qualitatively distinct symptoms, which could be applied in clinical practice. Safe use was documented. An anecdotal study supported the proposed efficacy of Hydroquinone for the treatment of vitiligo and further exploration could be carried out. Conclusion: The HPT of Hydroquinone brought in qualitative symptoms. It was noted that a potentized preparation could produce many functional symptoms, but could not produce degenerative pathological symptoms such as vitiligo. The preparation could be used by the profession for vitiligo on the basis of its toxicological effects, supported by the anecdotal study. The Quantitative and Qualitative Pathogenetic Indices could further be used in future HPTs as a tool.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded605    
    Comments [Add]    

Recommend this journal